S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

$4.52
-0.28 (-5.83%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$4.49
$4.87
50-Day Range
$4.52
$7.25
52-Week Range
$1.61
$7.45
Volume
1.41 million shs
Average Volume
1.51 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.16

Autolus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
80.5% Upside
$8.16 Price Target
Short Interest
Healthy
1.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Autolus Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to ($0.57) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

400th out of 908 stocks

Biological Products, Except Diagnostic Industry

55th out of 148 stocks

AUTL stock logo

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Stock Price History

AUTL Stock News Headlines

Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.2%
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Autolus Therapeutics (NASDAQ:AUTL) Trading Up 3.7%
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.86
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Q4 2023 Autolus Therapeutics PLC Earnings Call
Autolus Therapeutics's Earnings Outlook
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
463
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.16
High Stock Price Target
$11.00
Low Stock Price Target
$4.80
Potential Upside/Downside
+80.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-208,380,000.00
Pretax Margin
-12,273.38%

Debt

Sales & Book Value

Annual Sales
$1.70 million
Book Value
$0.64 per share

Miscellaneous

Free Float
197,583,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
1.90
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Christian Martin Itin Ph.D. (Age 60)
    CEO & Director
    Comp: $2.39M
  • Dr. Martin Pule M.D. (Age 52)
    MBBS, Founder, Senior VP & Chief Scientific Officer
  • Mr. Robert F. Dolski (Age 53)
    Senior VP & CFO
  • Mr. Christopher Vann (Age 59)
    Senior VP & COO
  • Mr. David Brochu (Age 68)
    Senior VP & Chief Technical Officer
  • Mr. Alexander Swan (Age 59)
    Senior VP & Chief Human Resources Officer
  • Mr. Brent Rice (Age 58)
    Senior VP, Chief Commercial Officer & Site Head of US
  • Ms. Olivia Manser
    Director of Investor Relations
  • Mr. Alex Driggs
    Senior VP of Legal Affairs & General Counsel and Secretary
  • Dr. Chris Williams (Age 44)
    Senior VP & Chief Business Development Officer

AUTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price target for 2024?

5 equities research analysts have issued 1-year price objectives for Autolus Therapeutics' shares. Their AUTL share price targets range from $4.80 to $11.00. On average, they predict the company's share price to reach $8.16 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2024?

Autolus Therapeutics' stock was trading at $6.44 at the beginning of 2024. Since then, AUTL shares have decreased by 29.8% and is now trading at $4.52.
View the best growth stocks for 2024 here
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.18.

What ETF holds Autolus Therapeutics' stock?

Harbor Disruptive Innovation ETF holds 93,201 shares of AUTL stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

Autolus Therapeutics (AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perpetual Ltd (0.84%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUTL) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners